Takeaways: Signia’s Multi‑adaptive Xperience (MaX) launch in Canada brings an AI‑driven, four‑DNN platform (speech, noise, environment, own‑voice) that the company says is the first of its kind ...
Takeaways: Health Canada’s approval of Imcivree (setmelanotide) for acquired hypothalamic obesity (HO) gives Rhythm Pharmaceuticals its first targeted therapy in Canada for this rare, injury‑dri...
Takeaways: Blair Health’s CAD $4.24M pre‑seed raise (total CAD $4.5M) gives it the capital to scale a “virtual specialist” model that encodes specialist‑designed pathways into software so genera...
Takeaways: Health Canada’s authorization of the XFG‑adapted Comirnaty vaccine for the 2026–2027 season keeps Pfizer/BioNTech aligned with national recommendations to match contemporary Omicron l...
Takeaways: Sandoz Canada’s Health Canada authorization for PrSandoz Semaglutide, a generic version of Ozempic, gives the country its first lower‑cost semaglutide option for type 2 diabetes...
Takeaways: Sanofi’s new Charles Best Building in Toronto adds end‑to‑end flu vaccine manufacturing capacity in Canada and is set to become the central hub for producing Fluzone High‑Dose for adu...
Takeaways: Optimi Health’s plan to start a Health Canada‑authorized Phase 3 trial of synthetic MDMA‑assisted therapy for PTSD in 2027 positions the company to potentially become an early mover i...
Takeaways: Health Canada’s acceptance of Knight Therapeutics’ New Drug Submission for Gemtesa (vibegron) moves the therapy closer to potential approval in Canada for adults with overactive bladd...
Takeaways: The first Canadian use of Abbott’s Volt Pulsed Field Ablation (PFA) System at McGill University Health Centre marks the start of commercial adoption of a next‑generation AFib therapy ...
Takeaways: Ontario’s FAST Program funding for Minjuvi (tafasitamab) plus R² gives eligible patients with relapsed or refractory follicular lymphoma earlier public access to a tar...
